GABRA1

GABRA1 is the gene that encodes the alpha-1 subunit of the gamma-aminobutyric acid type A receptor (GABA-A receptor). The GABA-A receptor is a ligand-gated chloride channel that mediates fast inhibitory neurotransmission in the central nervous system. The receptor is pentameric, typically comprising two alpha, two beta, and one gamma subunit; subunit composition determines channel properties, pharmacology, and localization. The alpha-1 subunit is highly expressed in many brain regions and contributes to the receptor’s assembly, trafficking, and sensitivity to benzodiazepines.

GABRA1 is located on chromosome 5q34. It is widely expressed in the brain, with strong presence in cortex and hippocampus, and shows developmental regulation consistent with neuronal maturation.

Pathogenic variants in GABRA1 have been linked to epileptic and neurodevelopmental disorders. Phenotypes include generalized epilepsy with febrile seizures plus (GEFS+), early-onset epilepsies, and cognitive or behavioral abnormalities such as intellectual disability and autism spectrum disorder. Most disease-associated variants are de novo or inherited in an autosomal dominant manner. Functional studies show loss-of-function effects, including reduced GABA-evoked currents, misfolding, or impaired receptor trafficking.

Clinical management aligns with other GABAergic epilepsies, often using antiseizure medications that enhance GABAergic signaling; benzodiazepines can be effective acutely, and drugs such as valproate may be used for longer-term control. Ongoing research uses patient-derived cells and animal models to elucidate genotype–phenotype relationships and to identify potential targeted therapies.